About PledPharma

PledPharma has an innovative, unique and integrated competence in pharmaceutical drug development with focus on improving treatments for severe diseases with substantial unmet medical need where alternative treatments does not exist.

About PledPharma

PledPharma has an innovative, unique and integrated competence in pharmaceutical drug development with focus on improving treatments for severe diseases with substantial unmet medical need where alternative treatments does not exist.

The company’s most advanced project PledOx® reduces nerve damage associated with chemotherapy. A phase III study started in November 2018.

The drug candidate Aladote® is developed to prevent acute liver failure associated with acetaminophen/paracetamol poisoning.

PledPharma (STO:PLED) is listed on Nasdaq First North.

PledOx®

- protects the peripheral nerves

Protection against the nerve damage that often occurs in connection with chemotherapy.

Aladote®

- protects the liver

Prevents acute liver failure in paracetamol poisoning.

Share

Facebook
Twitter
LinkedIn
RSS

Contact us

Address: Grev Turegatan 11 C, 114 46 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@pledpharma.com